Astria Therapeutics (NASDAQ:ATXS) Shares Up 6.8% – Should You Buy?

by · The Cerbat Gem

Astria Therapeutics, Inc. (NASDAQ:ATXS – Get Free Report) rose 6.8% during trading on Thursday . The company traded as high as $12.18 and last traded at $12.04. Approximately 181,621 shares traded hands during trading, a decline of 72% from the average daily volume of 644,293 shares. The stock had previously closed at $11.27.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on ATXS. HC Wainwright reaffirmed a “buy” rating and issued a $16.00 price objective on shares of Astria Therapeutics in a research report on Friday, September 27th. Oppenheimer upped their price target on Astria Therapeutics from $25.00 to $26.00 and gave the stock an “outperform” rating in a research note on Tuesday, August 13th. Evercore ISI raised Astria Therapeutics to a “strong-buy” rating in a research note on Wednesday, August 14th. Wedbush reaffirmed an “outperform” rating and set a $22.00 price target on shares of Astria Therapeutics in a research report on Tuesday, August 13th. Finally, TD Cowen started coverage on shares of Astria Therapeutics in a research note on Monday, July 29th. They issued a “buy” rating and a $35.00 target price on the stock. Five investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $25.20.

Check Out Our Latest Stock Report on ATXS

Astria Therapeutics Trading Up 5.0 %

The business has a 50-day moving average price of $11.54 and a two-hundred day moving average price of $10.48. The firm has a market capitalization of $649.62 million, a price-to-earnings ratio of -5.19 and a beta of 0.71.

Astria Therapeutics (NASDAQ:ATXS – Get Free Report) last issued its quarterly earnings data on Monday, August 12th. The biotechnology company reported ($0.43) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.05). On average, equities research analysts predict that Astria Therapeutics, Inc. will post -1.72 earnings per share for the current fiscal year.

Institutional Trading of Astria Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Quest Partners LLC lifted its position in shares of Astria Therapeutics by 3,310.6% in the 2nd quarter. Quest Partners LLC now owns 3,206 shares of the biotechnology company’s stock valued at $29,000 after acquiring an additional 3,112 shares in the last quarter. Ameritas Investment Partners Inc. boosted its position in Astria Therapeutics by 135.6% during the first quarter. Ameritas Investment Partners Inc. now owns 4,971 shares of the biotechnology company’s stock worth $70,000 after purchasing an additional 2,861 shares during the period. SG Americas Securities LLC acquired a new position in Astria Therapeutics during the third quarter valued at approximately $155,000. Hsbc Holdings PLC bought a new position in shares of Astria Therapeutics in the second quarter valued at approximately $171,000. Finally, Price T Rowe Associates Inc. MD bought a new position in Astria Therapeutics in the 1st quarter worth $200,000. 98.98% of the stock is owned by institutional investors and hedge funds.

Astria Therapeutics Company Profile

(Get Free Report)

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.

See Also